Docket No.: ACADIA.031A

Customer No. 20,995

INFORMATION DISCLOSURE STATEMENT

Applicant

Weiner et al.

App. No

10/761,787

Filed

January 21, 2004

For

USE OF N-DESMETHYLCLOZAPINE

TO TREAT HUMAN

NEUROPSYCHIATRIC DISEASE

Examiner

Jennifer M. Kim

Art Unit

1617

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 18 references to be considered by the Examiner. Also enclosed are 2 foreign references as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 12-20-07

By: Rya Melyir

Ryan E. Melnick Registration No. 58,621 Attorney of Record Customer No. 20,995 (619) 235-8550